{"id":"jr-131","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3646861","moleculeType":"Protein","molecularWeight":"1031.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JR-131 selectively inhibits fibroblast growth factor receptors, which are frequently dysregulated in various solid tumors through mutations, amplifications, or translocations. By blocking FGFR-mediated signaling pathways, the drug suppresses tumor cell proliferation and survival in FGFR-dependent malignancies. This mechanism is particularly relevant in cancers with FGFR alterations where the pathway drives oncogenic growth.","oneSentence":"JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:38.811Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT02912494","phase":"PHASE3","title":"A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2016-09","conditions":"Anemia","enrollment":""},{"nctId":"NCT02912533","phase":"PHASE3","title":"A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2016-09","conditions":"Anemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JR-131","genericName":"JR-131","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers. Used for FGFR-altered solid tumors (in clinical development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}